NanoViricides Inc. (NNVC)

[Rawnoc]

How many times have we heard they have sufficient money to get through clincals (at least phase I and II) only to see another equity raise? If one believes the notion presented here that it is prudent for a company to ensure their coffers are well stocked, then why doesn't the company stop presenting "sufficient funding" as a positive, as it obviously needs additional money to "be prudent."

My point was that there have been numerous posts (one today as a matter of fact) claiming the SP would be $10 as soon as they begin clinicals, yet there are numerous examples of companies in phase I or further, with similar solid financial footing, that are trading at cheaper market caps. CTIX is one good example.

Even with the reverse split taken into account, why is NNVC so much different?